{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:11:47Z","timestamp":1789593107917,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.jbspin.2014.07.010","type":"journal-article","created":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T21:46:41Z","timestamp":1410990401000},"page":"25-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"82","author":[{"given":"Yves-Marie","family":"Pers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxane","family":"Schaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Constant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Godfrin-Valnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Fortunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waafa","family":"Bourichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice Pallot","family":"Prades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wendling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gaudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francis","family":"Maillefert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Marotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2014.07.010_bib0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.rdc.2006.12.006","article-title":"Rheumatic disease in the elderly: rheumatoid arthritis","volume":"33","author":"Tutuncu","year":"2007","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0010","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nrrheum.2013.92","article-title":"The influence of ageing on the development and management of rheumatoid arthritis","volume":"9","author":"Boots","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/acr.21812","article-title":"Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis","volume":"65","author":"Widdifield","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0020","first-page":"234","article-title":"Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis","volume":"33","author":"Bathon","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0025","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/rheumatology\/kep291","article-title":"Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients","volume":"48","author":"Koller","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0030","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2165\/00002512-200623110-00001","article-title":"Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients","volume":"23","author":"Ornetti","year":"2006","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0035","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1136\/ard.2008.094730","article-title":"Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis","volume":"68","author":"Radovits","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/j.1875-9114.1990.tb02553.x","article-title":"Second-line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three controlled trials","volume":"10","author":"Dahl","year":"1990","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0045","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40266-013-0122-8","article-title":"Rheumatoid arthritis in the elderly in the era of tight control","volume":"30","author":"Soubrier","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0050","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1136\/ard.2011.151092","article-title":"Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients","volume":"70","author":"Koike","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0055","series-title":"EMARoActemra (tocilizumab). Summary of Product Characteristics","author":"EMA","year":"2014"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0060","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0065","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1297-319X(10)70001-4","article-title":"Tocilizumab: therapy and safety management","volume":"77","author":"Pham","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0070","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0085","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00063030-200923020-00004","article-title":"Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response","volume":"23","author":"Gibbons","year":"2009","journal-title":"BioDrugs"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0095","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/art.22688","article-title":"Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study","volume":"57","author":"Genevay","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0100","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/s10165-010-0366-7","article-title":"Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)","volume":"21","author":"Yamanaka","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/rheumatology\/ket301","article-title":"Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice","volume":"53","author":"Pers","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0110","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1136\/annrheumdis-2011-200838","article-title":"Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules","volume":"71","author":"Sakai","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/14740338.2011.537256","article-title":"Clinical safety of tocilizumab in rheumatoid arthritis","volume":"10","author":"Bannwarth","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0120","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","article-title":"Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials","volume":"50","author":"Campbell","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0125","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/ard.2007.079913","article-title":"Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis","volume":"67","author":"Radovits","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2014.07.010_bib0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/art.27740","article-title":"Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants","volume":"63","author":"Smolen","year":"2011","journal-title":"Arthritis Rheum"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X14001936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X14001936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T16:58:57Z","timestamp":1717347537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X14001936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1297319X14001936"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2014.07.010","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2014.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}